Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes
Authors
Schwaab, JNaumann, N
Luebke, J
Jawhar, M
Somervaille, Tim CP
Williams, Mark S
Frewin, R
Jost, PJ
Lichtenegger, FS
La Rosee, P
Storch, N
Haferlach, T
Horny, HP
Fabarius, A
Haferlach, C
Burchert, A
Hofmann, WK
Cross, NCP
Hochhaus, A
Reiter, A
Metzgeroth, G
Affiliation
Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.Issue Date
2020
Metadata
Show full item recordCitation
Schwaab J, Naumann N, Luebke J, Jawhar M, Somervaille TCP, Williams MS, et al. Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes. Am J Hematol. 2020.Journal
American Journal of HematologyDOI
10.1002/ajh.25825PubMed ID
32279331Additional Links
https://dx.doi.org/ 10.1002/ajh.25825Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1002/ajh.25825
Scopus Count
Collections
Related articles
- Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors--a single center experience.
- Authors: Ribeiro BF, Miranda EC, Albuquerque DM, Delamain MT, Oliveira-Duarte G, Almeida MH, Vergílio B, Silveira RA, Oliveira-Duarte V, Lorand-Metze I, De Souza CA, Pagnano KB
- Issue date: 2015 Aug
- Second-generation tyrosine kinase inhibitors combined with stem cell transplantation in patients with imatinib-refractory chronic myeloid leukemia.
- Authors: Zhao Y, Luo Y, Shi J, Cai Z, Huang H
- Issue date: 2014 Jun
- Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
- Authors: Jain P, Kantarjian H, Alattar ML, Jabbour E, Sasaki K, Nogueras Gonzalez G, Dellasala S, Pierce S, Verstovsek S, Wierda W, Borthakur G, Ravandi F, O'Brien S, Cortes J
- Issue date: 2015 Mar
- Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes.
- Authors: Schwaab J, Knut M, Haferlach C, Metzgeroth G, Horny HP, Chase A, Tapper W, Score J, Waghorn K, Naumann N, Jawhar M, Fabarius A, Hofmann WK, Cross NC, Reiter A
- Issue date: 2015 Feb
- Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
- Authors: Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, Goh YT, Rosti G, Nakamae H, Gallagher NJ, Hoenekopp A, Blakesley RE, Larson RA, Hughes TP
- Issue date: 2011 Sep